In a retrospective analysis by Miyajima et al. of 138 PCa patients who received high-dose-rate brachytherapy, the 70 patients who were diagnosed with IDC-P demonstrated significantly inferior BCR-free survival and cancer progression-free survival [35]. Here, BCR is linked to posterior cortical atrophy.